aTyr Pharma - LIFE Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LIFE shares.
View LIFE analyst ratings or view top-rated stocks.

2 brokers have issued 12-month target prices for aTyr Pharma's shares. Their LIFE share price forecasts range from $14.00 to $35.00. On average, they anticipate the company's share price to reach $24.50 in the next twelve months. This suggests a possible upside of 1,050.2% from the stock's current price.
View analysts price targets for LIFE or view top-rated stocks among Wall Street analysts.

aTyr Pharma's stock was trading at $7.47 on January 1st, 2022. Since then, LIFE stock has decreased by 71.5% and is now trading at $2.13.
View the best growth stocks for 2022 here.

aTyr Pharma saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 303,000 shares, a decline of 33.3% from the October 31st total of 454,600 shares. Based on an average trading volume of 83,600 shares, the short-interest ratio is presently 3.6 days.
View aTyr Pharma's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our LIFE earnings forecast.

aTyr Pharma, Inc. (NASDAQ:LIFE) issued its quarterly earnings results on Monday, August, 9th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.13.

aTyr Pharma shares reverse split before market open on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

3 employees have rated aTyr Pharma Chief Executive Officer Sanjay Shukla, M.D, M.S on Glassdoor.com. Sanjay Shukla, M.D, M.S has an approval rating of 100% among the company's employees. This puts Sanjay Shukla, M.D, M.S in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Precigen (PGEN), QUALCOMM (QCOM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

(LIFE) raised $76 million in an IPO on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

aTyr Pharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include VR Adviser LLC (37.38%), Telemetry Investments L.L.C. (1.72%), Renaissance Technologies LLC (0.66%), Marshall Wace LLP (0.61%), Dimensional Fund Advisors LP (0.59%) and Royal Bank of Canada (0.17%). Insiders that own company stock include Jill Marie Broadfoot, John K Clarke, Paul Schimmel and Sanjay Shukla.
View institutional ownership trends.

Shares of LIFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LIFE stock can currently be purchased for approximately $2.13.

aTyr Pharma (NASDAQ:LIFE) has a market capitalization of $60.97 million and generates $10.45 million in revenue each year. The biotechnology company earns $-33,770,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The official website for the company is www.atyrpharma.com. The biotechnology company can be reached via phone at (858) 731-8389, via email at investorrelations@atyrpharma.com, or via fax at 858-731-8394.